vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.

PACS Group, Inc. is the larger business by last-quarter revenue ($1.4B vs $950.5M, roughly 1.4× Astrana Health, Inc.). PACS Group, Inc. runs the higher net margin — 4.4% vs 0.7%, a 3.7% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 18.4%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 20.5%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

ASTH vs PACS — Head-to-Head

Bigger by revenue
PACS
PACS
1.4× larger
PACS
$1.4B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+24.5% gap
ASTH
42.9%
18.4%
PACS
Higher net margin
PACS
PACS
3.7% more per $
PACS
4.4%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
20.5%
PACS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
PACS
PACS
Revenue
$950.5M
$1.4B
Net Profit
$6.6M
$59.7M
Gross Margin
Operating Margin
1.9%
7.0%
Net Margin
0.7%
4.4%
Revenue YoY
42.9%
18.4%
Net Profit YoY
184.4%
3022.5%
EPS (diluted)
$0.12
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
PACS
PACS
Q4 25
$950.5M
$1.4B
Q3 25
$956.0M
$1.3B
Q2 25
$654.8M
$1.3B
Q1 25
$620.4M
$1.3B
Q4 24
$665.2M
$1.1B
Q3 24
$478.7M
$1.0B
Q2 24
$486.3M
$981.4M
Q1 24
$404.4M
$934.3M
Net Profit
ASTH
ASTH
PACS
PACS
Q4 25
$6.6M
$59.7M
Q3 25
$373.0K
$52.4M
Q2 25
$9.4M
$51.0M
Q1 25
$6.7M
$28.5M
Q4 24
$-7.8M
$1.9M
Q3 24
$16.1M
$15.6M
Q2 24
$19.2M
$-10.9M
Q1 24
$14.8M
$49.1M
Gross Margin
ASTH
ASTH
PACS
PACS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
17.1%
Q2 24
22.3%
Q1 24
21.2%
Operating Margin
ASTH
ASTH
PACS
PACS
Q4 25
1.9%
7.0%
Q3 25
2.0%
6.4%
Q2 25
3.1%
6.2%
Q1 25
3.3%
3.8%
Q4 24
0.1%
1.7%
Q3 24
5.9%
2.2%
Q2 24
6.2%
0.1%
Q1 24
7.5%
8.6%
Net Margin
ASTH
ASTH
PACS
PACS
Q4 25
0.7%
4.4%
Q3 25
0.0%
3.9%
Q2 25
1.4%
3.9%
Q1 25
1.1%
2.2%
Q4 24
-1.2%
0.2%
Q3 24
3.4%
1.5%
Q2 24
3.9%
-1.1%
Q1 24
3.7%
5.3%
EPS (diluted)
ASTH
ASTH
PACS
PACS
Q4 25
$0.12
$0.42
Q3 25
$0.01
$0.32
Q2 25
$0.19
$0.31
Q1 25
$0.14
$0.17
Q4 24
$-0.14
$-0.03
Q3 24
$0.33
$0.10
Q2 24
$0.40
$-0.07
Q1 24
$0.31
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
PACS
PACS
Cash + ST InvestmentsLiquidity on hand
$429.5M
$197.0M
Total DebtLower is stronger
$353.2M
Stockholders' EquityBook value
$779.3M
$946.8M
Total Assets
$2.2B
$5.6B
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
PACS
PACS
Q4 25
$429.5M
$197.0M
Q3 25
$463.4M
$355.7M
Q2 25
$342.1M
$294.2M
Q1 25
$260.9M
$287.5M
Q4 24
$290.8M
$157.7M
Q3 24
$350.3M
$49.5M
Q2 24
$327.7M
$73.4M
Q1 24
$337.3M
$81.2M
Total Debt
ASTH
ASTH
PACS
PACS
Q4 25
$353.2M
Q3 25
Q2 25
Q1 25
Q4 24
$411.9M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ASTH
ASTH
PACS
PACS
Q4 25
$779.3M
$946.8M
Q3 25
$775.5M
$871.3M
Q2 25
$765.5M
$806.8M
Q1 25
$745.4M
$750.2M
Q4 24
$712.7M
$709.6M
Q3 24
$704.6M
$660.0M
Q2 24
$678.9M
$572.1M
Q1 24
$653.5M
$128.0M
Total Assets
ASTH
ASTH
PACS
PACS
Q4 25
$2.2B
$5.6B
Q3 25
$2.2B
$5.6B
Q2 25
$1.4B
$5.5B
Q1 25
$1.3B
$5.5B
Q4 24
$1.4B
$5.2B
Q3 24
$1.3B
$4.5B
Q2 24
$1.3B
$3.9B
Q1 24
$1.2B
$3.9B
Debt / Equity
ASTH
ASTH
PACS
PACS
Q4 25
0.37×
Q3 25
Q2 25
Q1 25
Q4 24
0.58×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
PACS
PACS
Operating Cash FlowLast quarter
$-2.9M
$-3.4M
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
-0.06×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
PACS
PACS
Q4 25
$-2.9M
$-3.4M
Q3 25
$10.0M
$204.8M
Q2 25
$90.9M
$52.6M
Q1 25
$16.6M
$150.2M
Q4 24
$-10.9M
$64.6M
Q3 24
$34.0M
$209.2M
Q2 24
$23.2M
$34.8M
Q1 24
$6.0M
$58.8M
Free Cash Flow
ASTH
ASTH
PACS
PACS
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
PACS
PACS
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
PACS
PACS
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
PACS
PACS
Q4 25
-0.44×
-0.06×
Q3 25
26.69×
3.91×
Q2 25
9.65×
1.03×
Q1 25
2.48×
5.28×
Q4 24
33.78×
Q3 24
2.11×
13.39×
Q2 24
1.21×
Q1 24
0.40×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

PACS
PACS

Segment breakdown not available.

Related Comparisons